382 related articles for article (PubMed ID: 31299316)
1. ATM in DNA repair in cancer.
Jin MH; Oh DY
Pharmacol Ther; 2019 Nov; 203():107391. PubMed ID: 31299316
[TBL] [Abstract][Full Text] [Related]
2. The development of ataxia telangiectasia mutated kinase inhibitors.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
[TBL] [Abstract][Full Text] [Related]
3. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
[TBL] [Abstract][Full Text] [Related]
4. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
[TBL] [Abstract][Full Text] [Related]
5. Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.
Priya B; Ravi S; Kirubakaran S
Drug Discov Today; 2023 Aug; 28(8):103662. PubMed ID: 37302542
[TBL] [Abstract][Full Text] [Related]
6. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
Saha J; Wang M; Cucinotta FA
DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
[TBL] [Abstract][Full Text] [Related]
7. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
8. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
9. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
10. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.
Zhou Q; Howard ME; Tu X; Zhu Q; Denbeigh JM; Remmes NB; Herman MG; Beltran CJ; Yuan J; Greipp PT; Boughey JC; Wang L; Johnson N; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Cancer Res; 2021 Jun; 81(12):3333-3346. PubMed ID: 33597272
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
13. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
14. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
15.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
16. A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers.
Zhao K; Wang X; Xue X; Li L; Hu Y
PLoS Biol; 2020 Mar; 18(3):e3000666. PubMed ID: 32203529
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
[TBL] [Abstract][Full Text] [Related]
18. A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.
Zimmermann A; Zenke FT; Chiu LY; Dahmen H; Pehl U; Fuchss T; Grombacher T; Blume B; Vassilev LT; Blaukat A
Mol Cancer Ther; 2022 Jun; 21(6):859-870. PubMed ID: 35405736
[TBL] [Abstract][Full Text] [Related]
19. Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G
Mak JPY; Ma HT; Poon RYC
Mol Cancer Ther; 2020 Jan; 19(1):123-134. PubMed ID: 31597711
[TBL] [Abstract][Full Text] [Related]
20. Expression variations of DNA damage response genes ATM and ATR in blood cancer patients.
Parvez A; Mahjabeen I; Mehmood A; Khan AU; Nisar A; Kayani MA
Mol Genet Genomics; 2023 Sep; 298(5):1173-1183. PubMed ID: 37338595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
